© BusinessWire
24.09.2024
BLUE
LISTED
NASDAQ
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
News Preview
Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating e...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.09.2024
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva | Rating: Kaufen
News Preview
Original-Research: Valneva - von First Berlin Equity Research GmbH
24.09.2024 / 11:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
ERF
LISTED
EURONEXT
Eurofins Sustainability Services Introduces EUDR Deforestation Impact Assessment
News Preview
Eurofins Sustainability Services (Paris:ERF), a full-service provider for retailers, brands, and manufacturers of consumer products, has grown its extensive service offering to include a deforestation impact assessment. The European Union’s Deforestation Regulation (EUDR) aims to prevent the import and sale of products linked to deforestation in t...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
23.09.2024
DBV
LISTED
EURONEXT
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
News Preview
Châtillon, France, September 23, 2024...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
23.09.2024
QGEN
LISTED
NYSE
QIAGEN und Bode Technology treiben Nutzung der GEDmatch PRO Datenbank für forensische genetische Genealogie voran
News Preview
QIAGEN wählt Bode Technology als exklusiven globalen Vertriebspartner, um den Einsatz der Genealogie-Datenbank GEDmatch PRO in der Strafverfolgung und bei der Identifizierung menschlicher Überreste zu beschleunigen // Zusammenarbeit stellt sicher, dass das Hauptaugenmerk bei der Weiterentwicklung von GEDmatch PRO auf den Bedürfnissen forensischer G...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.09.2024
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - from First Berlin Equity Research GmbH
23.09.2024 / 15:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cert......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.09.2024
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - from First Berlin Equity Research GmbH
23.09.2024 / 15:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cert......
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
KDEV
LISTED
STO
Karolinska Development divests its holding in the Danish dermatology company Henlez
News Preview
STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces the divestment of all its shares in the portfolio company Henlez ApS. Following the transaction, Karolinska Development's investment portfolio consists of eleven holdings....
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
AMRX
LISTED
NASDAQ
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pel...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
ALM
LISTED
BME
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
News Preview
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), taking place in Amsterdam from September 25 to 28, 2024. This year, Almirall marks its 80th anniversary, celebrating eight decades of innovatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
ORY
LISTED
BME
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
News Preview
MADRID and CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that it will present today the final data from its Phase IIb PORTICO trial of vafidemstat...
Themefolio
Profiler
Peergroup
© Newsfile
23.09.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development
News Preview
Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With ex...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
23.09.2024
GNFT
LISTED
EURONEXT
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo®1 (...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.09.2024
CLBX
LISTED
AIMX
Angle PLC Announces Exclusive agreement for DNA NGS panel
News Preview
ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBEOption for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs with ctDNACombining the Parsortix system with comprehensive DNA molecular analysis opens up a broad range of pharma services opportunities GUILDFORD, SURREY / ACCESSWIRE / Sept...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
EVT
LISTED
XETR
Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlage - J.POD® Toulouse, France (EU)
News Preview
J.POD® Toulouse, France (EU) bringt disruptive, skalierbare, kontinuierliche Biologika-Herstellungstechnologie in die Region
Just – Evotec Biologics J.POD®-Technologie bietet einen Paradigmenwechsel in der Bioproduktion mit kosteneffizienten und flexiblen Lösungen für die klinische und kommerzielle Versorgung
Hamburg und Toulo......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
EVT
LISTED
XETR
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
News Preview
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
EVT
LISTED
XETR
Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
News Preview
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2024
EVT
LISTED
XETR
Just – Evotec Biologics eröffnet hochmoderne Biologika-Anlage - J.POD® Toulouse, France (EU)
News Preview
J.POD® Toulouse, France (EU) bringt disruptive, skalierbare, kontinuierliche Biologika-Herstellungstechnologie in die Region
Just – Evotec Biologics J.POD®-Technologie bietet einen Paradigmenwechsel in der Bioproduktion mit kosteneffizienten und flexiblen Lösungen für die klinische und kommerzielle Versorgung
Hamburg und Toulo......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
CHEMM
LISTED
CPH
ChemoMetec makes offer to buy Ovizio Imaging Systems SA
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
COLO B
LISTED
CPH
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
News Preview
Please see enclosed pdf....
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
News Preview
Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approachesSIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significanceIomab-B was wel...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
TRAW
LISTED
NASDAQ
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
News Preview
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.09.2024
EVT
LISTED
XETR
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
News Preview
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the regionJust - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutionsHAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
ORNBV
LISTED
HEL
213,285 Orion Corporation A shares converted into B shares
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE20 SEPTEMBER 2024 at 9.30 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2024
ASND
LISTED
NASDAQ
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
News Preview
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Asce...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
HELP
LISTED
NASDAQ
Cybin Provides Corporate Update on Upcoming Clinical Milestones
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones.
“We are making rapi...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2024
GNFT
LISTED
EURONEXT
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
News Preview
Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 19, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half-year 2024 financial results and provided a corpor...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
ERF
LISTED
EURONEXT
Eurofins Consumer Product Testing Laboratory in Boston Completes Significant Expansion
News Preview
Eurofins MTS Consumer Product Testing US, based in Norwood, Boston MA, has completed a significant expansion, doubling total laboratory space, increasing workforce by 30% and adding three new specialised laboratories focused on Softlines & Hardlines, Furniture, and Toys. Eurofins MTS Consumer Product Testing US joined the international network...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2024
BAVA
LISTED
CPH
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
News Preview
COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
HELP
LISTED
NASDAQ
Cybin Announces Completion of Previously Announced Share Consolidation
News Preview
Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company’s issued and o...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2024
CLBX
LISTED
AIMX
Angle PLC Announces Agreement with Recursion Pharmaceuticals
News Preview
New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
QGEN
LISTED
NYSE
QIAGEN erweitert Portfolio für digitales PCR-System QIAcuity um über 100 neue Assays auf seiner GeneGlobe‑Plattform
News Preview
QIAGEN führt über 100 neue, laborvalidierte QIAcuity digitale PCR Assays für Krebsforschung, vererbte genetische Störungen, Überwachung von Infektionskrankheiten und weitere Anwendungen ein // QIAcuitys digitale PCR ermöglicht den präzisen und sensitiven Nachweis gering verbreiteter Pathogene, erkennt Kopienzahl-Variationen und identifiziert selten...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
SN
LISTED
LSE
First cases using Smith+Nephew’s new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
OXB
LISTED
LSE
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
News Preview
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
BAVA
LISTED
CPH
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
News Preview
COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN® mpox vaccine (marketed as JYNNEOS® or IMVANEX®) to be supplied to countries in Africa impacted by the mpox outbreak. The doses wil...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
TRAW
LISTED
NASDAQ
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
News Preview
Three proposals, including a reverse stock split, were submitted and approved...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a preclinical study of ZL-1503, the company’s internally discovered IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
BAVA
LISTED
CPH
Le seul vaccin contre le choléra à dose unique au Canada est disponible dans tout le pays
News Preview
TORONTO, 17 sept. 2024 (GLOBE NEWSWIRE) -- Bavarian Nordic, l’un des principaux fournisseurs mondiaux de vaccins pour voyageurs, a annoncé aujourd’hui la disponibilité commerciale de VAXCHORA®, le seul vaccin oral à dose unique approuvé au Canada pour protéger contre le choléra, une infection intestinale soudaine et grave caractérisée par une dia...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
FYB
LISTED
XETR
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
News Preview
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
FYB
LISTED
XETR
Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien
News Preview
Pressemitteilung // 17. September 2024
Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien
Planegg-Martinsried – Die Formycon AG (FWB: FYB) wird auf dem diesjährigen Kongress der European Academy of Dermatology & Venerology (EADV), der vom 25. bis 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
FYB
LISTED
XETR
Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien
News Preview
Pressemitteilung // 17. September 2024
Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien
Planegg-Martinsried – Die Formycon AG (FWB: FYB) wird auf dem diesjährigen Kongress der European Academy of Dermatology & Venerology (EADV), der vom 25. bis 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
FYB
LISTED
XETR
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
News Preview
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also completed the first part of the clinical phase 1b/2a study GOAL-HF1, evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
KDEV
LISTED
STO
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
News Preview
STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented positive top-line results from a clinical Phase 1/2 study with a potential first-in-class treatment of the rare bone disease osteogenesis imperfecta (OI). The results show that the treatment...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2024
CLBX
LISTED
AIMX
Angle PLC Announces Notice of Interim Results and Webcast
News Preview
Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / September 17, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 Jun...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
News Preview
LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
Immunovia shared results from the model development study of its...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
IMMNOV
LISTED
STO
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
News Preview
LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
Immunovia shared results from the model development study of its...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
CALTX
LISTED
STO
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
News Preview
STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
COLO B
LISTED
CPH
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
News Preview
Please see enclosed pdf....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
Please read the full announcement in PDF...
Themefolio
Profiler
Peergroup
© EQS Newswire
16.09.2024
GXI
LISTED
XETR
EcoVadis Gold mit erneut verbesserter Punktzahl
News Preview
Gerresheimer: EcoVadis Gold mit erneut verbesserter Punktzahl
Gerresheimer unter den Top 3 % aller bewerteten Unternehmen
Gesamtergebnis auf 76/100 Punkten gesteigert
Auszeichnung unterstreicht konsequente Umsetzung der Nachhaltigkeitsstrategie
Düsseldorf, 16. September 2024. Gerresheimer, innovativer System- und Lösungsanbieter und globaler Par......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.09.2024
GXI
LISTED
XETR
EcoVadis Gold with further improved score
News Preview
Gerresheimer: EcoVadis Gold with further improved score
Gerresheimer among the top 3 % of all rated companies
Overall result increased to 76/100 points
Award underlines consistent implementation of the sustainability strategy
Düsseldorf, September 16, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the ph......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.09.2024
GXI
LISTED
XETR
EcoVadis Gold mit erneut verbesserter Punktzahl
News Preview
Gerresheimer: EcoVadis Gold mit erneut verbesserter Punktzahl
Gerresheimer unter den Top 3 % aller bewerteten Unternehmen
Gesamtergebnis auf 76/100 Punkten gesteigert
Auszeichnung unterstreicht konsequente Umsetzung der Nachhaltigkeitsstrategie
Düsseldorf, 16. September 2024. Gerresheimer, innovativer System- und Lösungsanbieter und globaler Par......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.09.2024
GXI
LISTED
XETR
EcoVadis Gold with further improved score
News Preview
Gerresheimer: EcoVadis Gold with further improved score
Gerresheimer among the top 3 % of all rated companies
Overall result increased to 76/100 points
Award underlines consistent implementation of the sustainability strategy
Düsseldorf, September 16, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the ph......
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
ASND
LISTED
NASDAQ
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
News Preview
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001)...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
TIL
LISTED
NASDAQ
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
News Preview
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung c...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
ORNBV
LISTED
HEL
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
News Preview
ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2024
GMAB
LISTED
CPH
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
News Preview
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.09.2024
IMCR
LISTED
NASDAQ
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
News Preview
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), includ...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
